Biocartis Group NV 0R72.IL Stock
Biocartis Group NV Price Chart
Biocartis Group NV 0R72.IL Financial and Trading Overview
Biocartis Group NV stock price | 0.3 EUR |
Previous Close | 0.54 EUR |
Open | 0.44 EUR |
Bid | 0.4 EUR x 0 |
Ask | 0.44 EUR x 0 |
Day's Range | 0.42 - 0.44 EUR |
52 Week Range | 0.42 - 2.12 EUR |
Volume | 1.66K EUR |
Avg. Volume | 161 EUR |
Market Cap | 39.76M EUR |
Beta (5Y Monthly) | 1.506513 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.92 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
0R72.IL Valuation Measures
Enterprise Value | 146.63M EUR |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 0.68584985 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 2.529 |
Enterprise Value/EBITDA | -3.596 |
Trading Information
Biocartis Group NV Stock Price History
Beta (5Y Monthly) | 1.506513 |
52-Week Change | -70.38% |
S&P500 52-Week Change | 20.43% |
52 Week High | 2.12 EUR |
52 Week Low | 0.42 EUR |
50-Day Moving Average | 0.61 EUR |
200-Day Moving Average | 0.76 EUR |
0R72.IL Share Statistics
Avg. Volume (3 month) | 161 EUR |
Avg. Daily Volume (10-Days) | 237 EUR |
Shares Outstanding | 93.56M |
Float | 86.28M |
Short Ratio | N/A |
% Held by Insiders | 6.64% |
% Held by Institutions | 27.71% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -112.77% |
Operating Margin (ttm) | -79.11% |
Gross Margin | -15.58% |
EBITDA Margin | -70.34% |
Management Effectiveness
Return on Assets (ttm) | -22.33% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 57.98M EUR |
Revenue Per Share (ttm) | 0.96 EUR |
Quarterly Revenue Growth (yoy) | -2.00000000000000000000000000000000% |
Gross Profit (ttm) | -10216000 EUR |
EBITDA | -40781000 EUR |
Net Income Avi to Common (ttm) | -65381000 EUR |
Diluted EPS (ttm) | -1.08 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 26.13M EUR |
Total Cash Per Share (mrq) | 0.28 EUR |
Total Debt (mrq) | 122.36M EUR |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 1.647 |
Book Value Per Share (mrq) | -0.326 |
Cash Flow Statement
Operating Cash Flow (ttm) | -44855000 EUR |
Levered Free Cash Flow (ttm) | -28536000 EUR |
Profile of Biocartis Group NV
Country | United Kingdom |
State | N/A |
City | Mechelen |
Address | Generaal de Wittelaan 11 B |
ZIP | 2800 |
Phone | 32 1 563 26 00 |
Website | https://www.biocartis.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 526 |
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Q&A For Biocartis Group NV Stock
What is a current 0R72.IL stock price?
Biocartis Group NV 0R72.IL stock price today per share is 0.3 EUR.
How to purchase Biocartis Group NV stock?
You can buy 0R72.IL shares on the IOB exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Biocartis Group NV?
The stock symbol or ticker of Biocartis Group NV is 0R72.IL.
Which industry does the Biocartis Group NV company belong to?
The Biocartis Group NV industry is Diagnostics & Research.
How many shares does Biocartis Group NV have in circulation?
The max supply of Biocartis Group NV shares is 93.92M.
What is Biocartis Group NV Price to Earnings Ratio (PE Ratio)?
Biocartis Group NV PE Ratio is now.
What was Biocartis Group NV earnings per share over the trailing 12 months (TTM)?
Biocartis Group NV EPS is -0.92 EUR over the trailing 12 months.
Which sector does the Biocartis Group NV company belong to?
The Biocartis Group NV sector is Healthcare.